Selected article for: "breath shortness fever and cardiovascular disease"
Author: Zhichao Feng; Jennifer Li; Shanhu Yao; Qizhi Yu; Wenming Zhou; Xiaowen Mao; Huiling Li; Wendi Kang; Xin Ouyang; Ji Mei; Qiuhua Zeng; Jincai Liu; Xiaoqian Ma; Pengfei Rong; Wei Wang
Title: The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis
  • Document date: 2020_4_10
    • ID: k65501xp_1
    Snippet: respectively), diabetes (17.4% and 6.7%, respectively), and cardiovascular disease (8.7% and 3.2%, respectively) and presented with fever (84.1% and 60.4%, respectively) and shortness of breath (10.1% and 3.8%, respectively) compared with those who did not. Nonspecific antiviral therapy did not prevent clinical progression to severe pneumonia, although fewer hypertensive patients on angiotensin-converting enzyme inhibitors or angiotensin-receptor.....
    Document: respectively), diabetes (17.4% and 6.7%, respectively), and cardiovascular disease (8.7% and 3.2%, respectively) and presented with fever (84.1% and 60.4%, respectively) and shortness of breath (10.1% and 3.8%, respectively) compared with those who did not. Nonspecific antiviral therapy did not prevent clinical progression to severe pneumonia, although fewer hypertensive patients on angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers (ACEI/ARB) therapy developed severe pneumonia in contrast with those on non-ACEI/ARB that hypertension without receiving ACEI/ARB therapy was an independent risk factor (odds ratio

    Search related documents:
    Co phrase search for related documents
    • angiotensin convert and cardiovascular disease: 1
    • angiotensin receptor and antiviral therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • angiotensin receptor and ARB therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • angiotensin receptor and breath shortness: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • angiotensin receptor and cardiovascular disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • angiotensin receptor and clinical progression: 1, 2, 3, 4, 5, 6, 7
    • angiotensin receptor and clinical progression prevent: 1
    • angiotensin receptor and enzyme inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • angiotensin receptor and nonspecific antiviral therapy: 1
    • angiotensin receptor and odd ratio: 1
    • angiotensin receptor and respectively breath shortness: 1
    • angiotensin receptor and respectively breath shortness respectively fever: 1
    • angiotensin receptor blocker and ARB therapy: 1, 2, 3, 4, 5, 6, 7, 8
    • angiotensin receptor blocker and cardiovascular disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • angiotensin receptor blocker and enzyme inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral therapy and ARB therapy: 1, 2
    • antiviral therapy and breath shortness: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral therapy and cardiovascular disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • antiviral therapy and clinical progression: 1, 2, 3, 4, 5, 6, 7, 8, 9